Aptar Pharma announced today that it acquired the worldwide writes to Pharmaxis’ proprietary Orbital inhaler. Pharmaxis designed its Orbital technology to deliver high-payload dry powder to the lungs, helping to meet the need to deliver high doses of drugs such as antibiotics. According to a news release, the Orbital inhaler allows payloads of up to […]
Mergers & Acquisitions
BD buys MedKeeper and its connected pharmacy software for IV workflow
BD (NYSE:BD) announced today that it acquired cloud-based pharmacy management application developer MedKeeper. Franklin Lakes, N.J.-based BD said in a news release that MedKeeper strategically complements its existing presence in the pharmacy, with solutions for compounding, logistics workflow, controlled substance management and inventory optimization. MedKeeper’s platform will be made part of BD’s existing portfolio of […]
Tandem Diabetes Care acquires infusion set maker Capillary Biomedical
Tandem Diabetes Care (Nasdaq:TNDM) announced that it acquired infusion set developer Capillary Biomedical. San Diego-based Tandem, a global insulin delivery and diabetes technology company, announced its intention to acquire Irvine, California-based Capillary last week. Financial terms for the deal were not disclosed. “Infusion sets provide people flexible options in insulin pump wearability, and we are […]
AbbVie enters partnership with iStar with option to acquire
AbbVie (NYSE:ABBV) announced today that it entered into a strategic alliance with iStar Medical over the MINIject device. The strategic transaction centers around helping to further develop and commercialize iStar’s MINIject minimally invasive glaucoma surgical (MIGS) device. It will also provide AbbVie with a chance to expand its eye care business through an option to […]
Vertex to acquire stem cell-derived diabetes treatment maker ViaCyte for $320M
Vertex Pharmaceuticals (Nasdaq:VRTX) announced today that it agreed to acquire ViaCyte for $320 million. San Diego-based ViaCyte develops an advanced portfolio of novel stem cell-derived replacement therapies designed to provide a functional cure for patients with type 1 diabetes. Boston-based Vertex develops its own similar therapeutic for diabetes, having designed its VX-880 as a stem […]
Dexcom quashes talk of Insulet merger, says discussions are not ongoing
Dexcom (Nasdaq:DXCM) today issued a statement denying recent rumors of a potential merger with Insulet (Nasdaq:PODD). Last week, reports circulated saying talks over a potential acquisition were ongoing, with an agreement between the two diabetes technology developers on the horizon in the coming weeks. On the back of the Dexcom statement, DXCM shares were up 7% at $308.87 apiece […]
Report: Dexcom in talks to acquire Insulet
Major players in the diabetes space could join forces as Dexcom (Nasdaq:DXCM) is reportedly in discussions to acquire Insulet (Nasdaq:PODD). Bloomberg reported today that people “with knowledge of the matter” have said talks are ongoing over a potential acquisition and even said an agreement could be reached “in the coming weeks.” Bloomberg said its sources preferred […]
Medtronic completes Intersect ENT acquisition
Medtronic (NYSE:MDT) announced that it completed its previously announced $1.1 billion acquisition of Intersect ENT (Nasdaq:XENT). Fridley, Minnesota-based Medtronic announced in August 2021 that it would acquire all outstanding shares of the Menlo Park, Calif.-based sinus implant maker for $28.25 per share in an all-cash transaction. As a result of the transaction, Medtronic acquires Intersect ENT’s Propel and Sinuva drug-eluting […]
Halozyme acquires Antares Pharma for $960M to create drug delivery company
Halozyme Therapeutics (Nasdaq:HALO) announced today that it will acquire Antares Pharma (Nasdaq:ATRS) for approximately $960 million. Both companies’ boards of directors approved the transaction, which will see Halozyme acquire Antares for $5.60 per share in cash. According to a news release, the business combination will create a leading drug delivery and specialty product company with […]
How Embecta is ‘uniquely positioned’ in diabetes space following spinoff from BD
Unlike most “new” companies, Embecta enters the playing field with nearly a century of history in diabetes. Nearly one year after BD (NYSE:BDX) announced its intent to spinoff its diabetes business, Embecta (Nasdaq:EMBC) now stands on its own. On April 1, the spinoff was made official, and Embecta became a standalone, publicly-traded company aiming to […]
